Navigation Links
YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results
Date:2/10/2011

e, 47% achieved a minimum 50% decrease in palpable spleen size, qualifying for Clinical Improvement (CI) per IWG-MRT criteria. - CYT387 controlled constitutional symptoms in a significant percentage of patients (night sweats: 88%, bone pain 80%, pruritus: 92%, fever: 100%). - Of 42 subjects who were evaluable for anemia response, 50% had achieved CI as per IWG-MRT criteria. A 57% response rate was observed in transfusion-dependent patients. - Full enrollment of 140 patients into the trial is anticipated in calendar Q1 2011. To date, 111 patients have been enrolled into the study. The Company anticipates that an additional set of updated interim data will be reported in the second quarter of calendar 2011 and a full data set will be reported by the end of calendar 2011. The Company is also working towards completing in calendar 2011 any preclinical and manufacturing activities required to enable CYT387 to commence a Phase III pivotal trial in calendar Q1 2012.

Nimotuzumab:

- Daiichi Sankyo Co., Ltd., CIMYM's licensee for nimotuzumab in Japan, previously initiated a randomized trial with nimotuzumab in second line gastric cancer, together with Kuhnil Pharma Co. Ltd., CIMYM's licensee in Korea. Data from this trial were presented in January 2011 at the ASCO Gastrointestinal Cancers Symposium and demonstrated an improvement in Progression Free Survival in a subset of patients whose tumors were EGFR-positive. Should Daiichi Sankyo indicate an interest in advancing nimotuzumab into a Phase III clinical trial in gastric cancer, it could initiate in calendar 2012 subject to achieving commercial-scale production. Daiichi Sankyo also launched a Phase II trial in first-line treatment of advanced NSCLC for which YM has been advised that recruitment has been completed, with data expected during the first half of calendar 2011. - Oncoscience AG (OSAG), CIMYM's licensee for Europe, has advised that data from a Phase III trial in adult glioma patients may be repor
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
2. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
3. YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI Symposium
4. Ardea Biosciences Prices Public Offering of Common Stock
5. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
6. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
7. Whitney M. Young, Jr. Health Services and Magellan Biosciences Partner to Provide Three-Minute LeadCare II Blood-Lead Screenings to Berlin Elementary Students
8. YM BioSciences Closes Public Offering of Common Shares
9. YM BIOSCIENCES PRICES $40 MILLION PUBLIC OFFERING
10. Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen
11. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... patient has sepsis, a life-threatening condition in which bacteria ... too fast for antibiotics to help. A new device ... team at Harvard,s Wyss Institute for Biologically Inspired Engineering ... , "Even with the best current treatments, sepsis patients ... percent of the time," said Mike Super, Ph.D., Senior ...
(Date:9/15/2014)... Calif. , Sept. 15, 2014 ... new viral transport solution for safe ambient temperature ... to molecular testing. Importantly, the infectivity of agents in ... while maintaining the integrity of the viral nucleic ... of the recent Ebola epidemic in ...
(Date:9/15/2014)... CA (PRWEB) September 15, 2014 ... term implantable silicones for the medical device and ... silicone gel for the implantable medical device market. ... unique crosslink technology delivering a silicone gel with ... The Dual Matrix technology consists of two crosslinked ...
(Date:9/15/2014)... Sept. 15, 2014  The second annual International ... 12-18. A joint initiative of the Plasma Protein ... , IPAW is designed to: , Raise ... the contributions of plasma donors in saving and improving ... therapies and rare diseases Member companies ...
Breaking Biology Technology:Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3
... , Key ... • receptor binding assay • LEADseeker • ... The α 2 -adrenergic receptors are G protein-coupled receptors ... as renal Na + re-absorption, insulin secretion, platelet aggregation, and neurotransmitter release ...
... Key words: NK2 • GPCR ... SPA Imaging Beads , ... a family of small neuropeptides. Members of this family include peptides, substance ... hemokinin-1 (1). Neurokinins are widely distributed throughout the central and peripheral nervous ...
... Key words: formalin-fixed ... degenerate oligonucleotideprimed PCR (DOP-PCR),• Cy3/Cy5-dCTP probe labeling • comparative,genomic ... array CGH , ... Human genomic DNA isolated from formalin-fixed paraffin-embedded (FFPE) tissue ...
Cached Biology Technology:Development of an adrenergic α2a receptor binding assay using the LEADseeker Multimodality Imaging System 2Development of an adrenergic α2a receptor binding assay using the LEADseeker Multimodality Imaging System 3Development of an adrenergic α2a receptor binding assay using the LEADseeker Multimodality Imaging System 4Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System 2Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System 3Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System 4GenomiPhi amplification of FFPE tissue DNA for array CGH 2GenomiPhi amplification of FFPE tissue DNA for array CGH 3GenomiPhi amplification of FFPE tissue DNA for array CGH 4GenomiPhi amplification of FFPE tissue DNA for array CGH 5GenomiPhi amplification of FFPE tissue DNA for array CGH 6GenomiPhi amplification of FFPE tissue DNA for array CGH 7GenomiPhi amplification of FFPE tissue DNA for array CGH 8GenomiPhi amplification of FFPE tissue DNA for array CGH 9GenomiPhi amplification of FFPE tissue DNA for array CGH 10
(Date:9/16/2014)... fall marks a new school year, a new football ... Space Station. In September, SpaceX,s Dragon spacecraft is scheduled ... and investigations as part of the company,s fourth contracted ... will be the third suite of research investigations sponsored ... Space (CASIS). With the role of managing the U.S. ...
(Date:9/16/2014)... of interaction between viruses, bacteria, and their environment ... international collaboration between Matthew Sullivan, associate professor in ... Evolutionary Biology and Steven Hallam from the University ... "Bacteria are drivers of nutrient and energy cycles ... climate is changing, so are the environments these ...
(Date:9/16/2014)... pipeline (KXL) would likely increase oil sands extraction, according ... the non-profit organization Near Zero. The results are detailed ... includes both supporters and opponents of the pipeline. ... lead to significantly higher greenhouse gas emissions, with the ... , "This report examines three main scenarios discussed by ...
Breaking Biology News(10 mins):CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3Keystone XL would likely raise oil sands production and greenhouse gas emissions 2
... are often seen laughing and smiling, but this cheerful ... and seizures. , ,ew research in mice, ... alleviated. , Edwin Weeber, Ph.D., and colleagues reversed ... syndrome by preventing the inhibition of CaMKII, an enzyme ...
... sea levels in the centuries to come? Are we destroying ... oceans on the rise? Can aquaculture be environmentally sustainable? And ... coastal fisheries? , Most importantly, what can governments, industry and ... media are invited to join leading international researchers and government ...
... winner of the 2006 David Horrobin Prize for medical ... Assumption and No Two Alike, the article, "Parental selection: ... hairlessness and skin color" was judged to best embody ... in 2004, is awarded annually and named in honour ...
Cached Biology News:Angelman syndrome deficits rescued in mice 2Angelman syndrome deficits rescued in mice 3Are we killing the world's oceans? 2Why aren't humans furry? Stone-Age moms could be the answer 2
Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
Mouse polyclonal antibody raised against a partial recombinant SYT4. NCBI Entrez Gene ID = 6860...
Mouse monoclonal antibody raised against a partial recombinant IL31RA. NCBI Entrez Gene ID = IL31RA...
...
Biology Products: